New triple inhaler shows promise for advanced COPD lungs

NCT ID NCT04876677

Completed Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether switching to a stronger, extrafine triple inhaler (CHF5993) could improve lung function in 25 people with advanced COPD. Participants were current or former smokers aged 40 or older. The study used special lung imaging to measure changes in airway volume and airflow resistance.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Contacts and locations

Show contact details

Locations

AZ Delta

Roeselare, Belgium
AZ Zeno Knokke-Heist

Knokke, Belgium
CRU Hungary Ltd

Miskolc, Hungary
Dr. Kenessey Albert Hospital

Balassagyarmat, Hungary
Medlmprove BV

Kontich, 2550, Belgium
National Koranyi Institute for TB and Pulmonology

Budapest, Hungary
OLV Hospital Aalst

Aalst, Belgium
Pneumocare Scrl

Erpent, Belgium